Which of the following oral diabetes treatments are associated with high risks of hypoglycemia?

Rationale: A. DPP-4 inhibitors work by increasing incretin levels, which stimulates insulin release only in a glucose-dependent manner. This means they do not trigger significant insulin secretion when blood sugar levels are normal or low. Consequently, they carry a very low risk of causing hypoglycemia when used as monotherapy, making them a safe choice for elderly or high-risk patients. B. GLP-1 receptor agonists also utilize a glucose-dependent mechanism to enhance insulin secretion and suppress glucagon production. They do not force the pancreas to release insulin if the circulating glucose concentration is already low. This pharmacological profile ensures that the drug effectively lowers high blood sugar without pushing the patient into a hypoglycemic state during fasting or exercise. C. SGLT-2 inhibitors lower blood glucose by promoting the excretion of glucose in the urine rather than by increasing insulin levels. Because they do not stimulate the pancreas or increase insulin sensitivity directly, they do not typically cause hypoglycemia. They are valued in clinical practice for providing glycemic control and cardiovascular benefits without the safety concerns associated with traditional insulin secretagogues. D. Sulfonylureas work by binding to the SUR1 subunit of the ATP-sensitive potassium channels in pancreatic beta cells, forcing a continuous secretion of insulin regardless of blood glucose levels. This non-glucose-dependent mechanism means that insulin continues to be released even when blood sugar is low, significantly increasing the risk of severe and prolonged hypoglycemia. They require careful patient education regarding consistent carbohydrate intake.